SCHEMBL1879142

SCHEMBL1879142

Nc1nc(-c2cccc(OCc3cccc(OC(F)(F)F)c3)c2)c2cc(Cl)ccc2n1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.48
HSP90AB1 P08238 1/20 0.44
SLC9A3 P48764 1/20 0.44
DHFR P00374 3/20 0.43
ADORA2A P29274 2/20 0.43
MAOB P27338 1/20 0.41
DCPS Q96C86 2/20 0.40
IGF1R P08069 2/20 0.40
P2RY14 Q15391 1/20 0.39
PKM P14618 1/20 0.39
XDH P47989 1/20 0.39
DHODH Q02127 1/20 0.38
NR1H2 P55055 3/20 0.38
CSNK2A2 P19784 1/20 0.38
CSNK2B P67870 1/20 0.38
CYP19A1 P11511 1/20 0.38
CYP11B1 P15538 1/20 0.38
CYP11B2 P19099 1/20 0.38
NR1H3 Q13133 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1879428 0.92 BACE1 (0.48) BACE1HSP90AB1SLC9A3DHFRADORA2A
SCHEMBL1881986 0.89 DHFR (0.55) BACE1HSP90AB1SLC9A3DHFRADORA2A
SCHEMBL1875717 0.89 NR1H2 (0.49) BACE1HSP90AB1SLC9A3DHFRADORA2A
SCHEMBL1877258 0.88 BACE1 (0.52) BACE1HSP90AB1SLC9A3DHFRADORA2A
SCHEMBL1879985 0.86 BACE1 (0.55) BACE1HSP90AB1SLC9A3DHFRADORA2A
SCHEMBL1879206 0.85 BACE1 (0.49) BACE1HSP90AB1SLC9A3DHFRADORA2A
SCHEMBL1879741 0.85 HSP90AB1 (0.55) BACE1HSP90AB1SLC9A3DHFRADORA2A
SCHEMBL1879323 0.85 BACE1 (0.48) BACE1HSP90AB1SLC9A3DHFRADORA2A
SCHEMBL1877697 0.84 BACE1 (0.52) BACE1HSP90AB1SLC9A3DHFRADORA2A
SCHEMBL1871638 0.83 ADORA2A (0.53) BACE1HSP90AB1SLC9A3DHFRADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7947696-B2 heat shock proteins inhibition, regulation and/or modulation; tumour diseases, viral diseases, for immune suppression in transplants, inflammation-induced diseases, cystic fibrosis, diseases associated with angiogenesis, infectious diseases, autoimmune diseases, ischaemia, fibrogenetic diseases MERCK PATENT GMBH (DE) 2011-05-24 US claimed
US-20080214586-A1 2-Amino-4-Phenylquinazoline Derivatives and the Use Thereof as Hsp90 Modulators MERCK PATENT GMBH (DE) 2008-09-04 US claimed
CN-101180278-A 2-amino-4-phenylquinazoline derivates and their use as HSP90 modulators MERCK PATENT GMBH (DE) 2008-05-14 CN claimed
US-7947696-B2 heat shock proteins inhibition, regulation and/or modulation; tumour diseases, viral diseases, for immune suppression in transplants, inflammation-induced diseases, cystic fibrosis, diseases associated with angiogenesis, infectious diseases, autoimmune diseases, ischaemia, fibrogenetic diseases MERCK PATENT GMBH (DE) 2011-05-24 US disclosed
CN-101180278-B 2-amino-4-phenylquinazoline derivates and their use as HSP90 modulators MERCK PATENT GMBH 2011-05-04 CN disclosed
US-20080214586-A1 2-Amino-4-Phenylquinazoline Derivatives and the Use Thereof as Hsp90 Modulators MERCK PATENT GMBH (DE) 2008-09-04 US disclosed
CN-101180278-A 2-amino-4-phenylquinazoline derivates and their use as HSP90 modulators MERCK PATENT GMBH (DE) 2008-05-14 CN disclosed
EP-1881965-A1 2-AMINO-4-PHENYLQUINAZOLINE DERIVATES AND THEIR USE AS HSP90 MODULATORS Merck Patent GmbH (DE) 2008-01-30 EP disclosed
WO-2006122631-A1 2-AMINO-4-PHENYLQUINAZOLINE DERIVATES AND THEIR USE AS HSP90 MODULATORS MERCK PATENT GMBH (DE) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214586-A1 2-Amino-4-Phenylquinazoline Derivatives and the Use Thereof as Hsp90 Modulators HSP90AB2P, HSP90AB1, HSP90AA1 BACE1 4518/4885HSP90AB1 2/4885SLC9A3 2685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.